Clinical trial
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
NCT00288704 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00288704 |
|---|---|
| Title | Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) |
| Official title | IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn |
| Intervention type | Drug |
| Interventions | rilonacept 160 mg, Placebo |
| Enrollment | 104 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 8, 2006 |
| Last update posted | Dec 6, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: